CAZypedia celebrates the life of Senior Curator Emeritus Harry Gilbert, a true giant in the field, who passed away in September 2025.


CAZypedia needs your help!

We have many unassigned pages in need of Authors and Responsible Curators. See a page that's out-of-date and just needs a touch-up? - You are also welcome to become a CAZypedian. Here's how.
Scientists at all career stages, including students, are welcome to contribute.
Learn more about CAZypedia's misson here and in this article. Totally new to the CAZy classification? Read this first.

Polysaccharide Lyase Family 38

From CAZypedia
Jump to navigation Jump to search

This page has been approved by the Responsible Curator as essentially complete. CAZypedia is a living document, so further improvement of this page is still possible. If you would like to suggest an addition or correction, please contact the page's Responsible Curator directly by e-mail.


Polysaccharide Lyase Family 38
3D structure ( α / α )7 barrel
Mechanism syn and anti β-elimination
Charge neutralizer Asn
Active site residues Tyr (syn proton abstraction and donation), His (anti proton abstraction)
CAZy DB link
https://www.cazy.org/PL38.html



Substrate specificities

PL38 is a multispecific family whose characterised members act on one of two distinct uronic acid polysaccharides: Glucuronates (β-1,4-glucuronan, EC 4.2.2.14) or alginate (β-1,4-mannuronate/α-1,4-guluronate, EC 4.2.2.3, 4.2.2.11, 4.2.2.-). CUL-I, from Brevundimonas sp. SH203, the founding member of PL38 (distantly related to PL5), specifically depolymerises the β-1,4-glycoside linkages of β-D-1,4-glucuronan prepared by TEMPO-mediated oxidation from regenerated cellulose, and does not act on the structurally related α-1,4-polyglucuronate or β-1,3-polyglucuronate. Its mode of action is endo-type, consistent with production of a distribution of oligosaccharide products [1].

TpPL38A from Trichoderma parareesei is a glucuronan lyase (EC 4.2.2.14) acting on β-1,4-polyglucuronic acid, and displays an exo-lytic mode of action [2].

The discovery of Aly38A from Agarivorans sp. B2Z047 revealed that PL38 is not restricted to glucuronan substrates. Aly38A was the first alginate lyase belonging to the PL38 family, as demonstrated by TLC analysis, which showed it degrades sodium alginate, polyM (β-D-polymannuronate), and polyG (α-L-polyguluronate) [3].

BoPL38 from Bacteroides ovatus CP926 was found to degrade well-characterised alginates, polyM-, polyG-, and polyMG-substrates in endo-mode, with the ability to cleave G-G, M-M, and M-G/G-M glycosidic linkages. The most prominent products of BoPL38 action are oligosaccharides of DP5–6, and hardly any DP1 (unsaturated monouronate) is formed, consistent with a strict endo-lytic mode. Notably, BoPL38 did not degrade β-1,4-glucuronan, indicating that alginate specificity and glucuronan specificity represent distinct substrate preferences within the family [4].

Mechanism

PL38 enzymes operate via a β-elimination mechanism, producing oligosaccharides with a new non-reducing end with a 4-deoxy-L-erythro-hex-4-en pyranosyl uronate residue (Δ). This unsaturated uronate is characteristic of polysaccharide lyases acting on uronic acid-containing substrates.

The mechanism traditionally follows three steps: (I) charge neutralisation of the uronate carboxyl, which in some PL families is assisted by metal cations, such as Ca2+. In PL38, the function of charge neutralisation is taken by an Asn residue. (II) general base-catalyzed abstraction of the proton on the C5 and (III) β-elimination of the 4-O-glycosidic bond [5].

The mechanistic analysis of BoPL38 revealed that a single active site architecture can facilitate both syn- and anti-β-elimination. C5 proton abstraction at subsite +1 is carried out by Y298 (enabling syn-β-elimination) and H243 (enabling anti-β-elimination), and the two pathways proceed through distinct transition states. In the syn reaction, the general base abstracts the H5 proton from the uronate moiety at subsite +1 on the same side as the glycosidic oxygen, while in the anti-reaction they are on opposite sides. This dual mechanism allows BoPL38 to process both mannuronate and guluronate blocks, which differ in the relative orientation of the C5 hydrogen and the glycosidic oxygen [6].

R292 plays a critical role in BoPL38, distorting the sugar at subsite +1 into a preactivated conformation, while also stabilising the active site tunnel through a salt bridge. A well-defined residue network mediates substrate recognition, and site-directed mutagenesis confirmed that disruption of this network destabilises the active site architecture [6].

NMR spectroscopy revealed that BoPL38 also catalyses mannuronate-to-guluronate epimerization, a secondary activity that had not previously been reported in any alginate lyase. As in lyase-catalysed β-elimination, the epimerization reaction initiates with H5 abstraction; however, instead of cleaving the glycosidic linkage, a proton is donated back to C5 from the opposite face, inverting the configuration at that center [6].

For the exo-lytic glucuronan lyase TpPL38A, NMR analysis showed that the monomeric unsaturated end-product undergoes spontaneous rearrangement to tautomeric forms, a non-enzymatic phenomenon that follows product release and has also been observed in alginate [2, 7].

Optimal activity conditions differ between characterised members. BoPL38 has an activity optimum at pH 7.5 [4], while TpPL38A displays optimal activity at pH 6 [2].

Catalytic Residues

The catalytic residues of PL38 have been established through the combined structural, computational, and mutagenesis analysis of BoPL38 from Bacteroides ovatus CP926 [6].

The uronate carboxyl charge neutralising residue is Asn242 (BoPL38 numbering), Y298 (enabling syn-β-elimination) and H243 (enabling anti-β-elimination). Based on the mechanistic study of BoPL38, Arg292 seems to be essential for maintaining Tyr298's protonation state, distorting the uronate in the +1 subsite, and maintaining the tunnel architecture of the enzyme [6]. However, this has only been described for the alginate lyase, BoPL38.

Three-dimensional structures

The first three-dimensional structure of a PL38 protein was determined without associated publication by the Joint Center for Structural Genomics (JCSG) for an uncharacterized Bacteroides ovatus ATCC 8483 protein (PDB: 3NFV and 3NNB). BoPL38 was found to be very similar to this uncharacterized PL38 structure, sharing the residues desctibed above [4]. PL38 is an ( α / α )7 barrel with an electronegative tunnel formed by two loop regions.

Michaelis complexes of BoPL38 with alginate oligosaccharides hexaguluronate (PDB: 9FHT), hexamannuronate (PDB: 9FHU), and a hexameric alternating M-G block (PDB: 9FHV) were resolved by X-ray crystallography at pH 3.5, far from the catalytic optimum. These complexes confirmed the location of the active site in the electropositive tunnel of the (α/α)₇-barrel fold. The alginate oligosaccharides are visible in the electron density, binding at the same subsites, with most M units adopting the canonical ⁴C₁ chair conformation and G units at subsites –1 and +1 found in the ²S₀ skew-boat conformation. The distortion of the +1 sugar into a non-standard ring conformation is consistent with a preactivation mechanism preceding catalysis [6].

No three-dimensional structure has been reported to date for the glucuronan-active PL38 members CUL-I or TpPL38A, and structural comparison between the glucuronan-specific and alginate-specific subfamilies within PL38 remains an open question.

Family Firsts

First description of catalytic activity
  • (1,4)-β-D-glucuronan activity by Brevundimonas sp. SH203 cellouronate lyase (CUL-I) [1].
  • Sodium-alginate, poly-mannuronate and poly-guluronate activity by Agarivorans sp. B2Z047 alginate lyase (Aly38A) [3].
First catalytic residues and charge neutralizer
Bacteroides ovatus CP926 alginate lyase (BoPL38) [6].
First 3-D structure
Bacteroides ovatus ATCC 8483 PL38 (PDB 3NFV and 3NNB), published by the Joint Center for Structural Genomics (JCSG) [No associated publication].

References

  1. Kikuchi M, Konno N, Suzuki T, Fujii Y, Kodama Y, Isogai A, and Habu N. A bacterial endo-β-1,4-glucuronan lyase, CUL-I from Brevundimonas sp. SH203, belonging to a novel polysaccharide lyase family. Protein Expr Purif. 2020 Feb;166:105502. DOI:10.1016/j.pep.2019.105502 | PubMed ID:31546007 [kikuchi2019]
  2. Pilgaard B, Vuillemin M, Munk L, Holck J, Meier S, Wilkens C, and Meyer AS. Discovery of a Novel Glucuronan Lyase System in Trichoderma parareesei. Appl Environ Microbiol. 2022 Jan 11;88(1):e0181921. DOI:10.1128/AEM.01819-21 | PubMed ID:34705548 [Pilgaard2022]
  3. Sun XK, Gong Y, Shang DD, Liu BT, Du ZJ, and Chen GJ. Degradation of Alginate by a Newly Isolated Marine Bacterium Agarivorans sp. B2Z047. Mar Drugs. 2022 Apr 4;20(4). DOI:10.3390/md20040254 | PubMed ID:35447927 [Sun2022]
  4. Rønne ME, Tandrup T, Madsen M, Hunt CJ, Myers PN, Moll JM, Holck J, Brix S, Strube ML, Aachmann FL, Wilkens C, and Svensson B. Three alginate lyases provide a new gut Bacteroides ovatus isolate with the ability to grow on alginate. Appl Environ Microbiol. 2023 Oct 31;89(10):e0118523. DOI:10.1128/aem.01185-23 | PubMed ID:37791757 [Ronne2023]
  5. Gacesa P. (1987) Alginate‐modifying enzymes: A proposed unified mechanism of action for the lyases and epimerases. FEBS Letters, 212, 1873-3468. DOI:10.1016/0014-5793(87)81344-3 [Gacesa1987]
  6. Tandrup T, Rivas-Fernández JP, Madsen M, Rønne ME, B Petersen A, Klau LJ, Tøndervik A, Wilkens C, Aachmann FL, Rovira C, and Svensson B. The Swiss Army Knife of Alginate Metabolism: Mechanistic Analysis of a Mixed-Function Polysaccharide Lyase/Epimerase of the Human Gut Microbiota. J Am Chem Soc. 2025 Jul 9;147(27):23594-23607. DOI:10.1021/jacs.5c03557 | PubMed ID:40570315 [Tandrup2025]
  7. Arntzen MØ, Pedersen B, Klau LJ, Stokke R, Oftebro M, Antonsen SG, Fredriksen L, Sletta H, Aarstad OA, Aachmann FL, Horn SJ, and Eijsink VGH. Alginate Degradation: Insights Obtained through Characterization of a Thermophilic Exolytic Alginate Lyase. Appl Environ Microbiol. 2021 Feb 26;87(6). DOI:10.1128/AEM.02399-20 | PubMed ID:33397696 [Arntzen2021]

All Medline abstracts: PubMed